BiotechTube

Dulaglutide + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiovascular Disease

Conditions

Cardiovascular Disease, Diabetes Mellitus, Type 2

Trial Timeline

Jul 22, 2011 → Aug 21, 2018

NCT ID
NCT01394952

About Dulaglutide + Placebo

Dulaglutide + Placebo is a phase 3 stage product being developed by Eli Lilly for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01394952. Target conditions include Cardiovascular Disease, Diabetes Mellitus, Type 2.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Disease were approved

Approved (9) Terminated (2) Active (9)
🔄polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
🔄raloxifene + placeboEli LillyPhase 3
🔄Orforglipron + PlaceboEli LillyPhase 3
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT03315780ApprovedCompleted
NCT02963766Phase 3Completed
NCT02973100Phase 2Completed
NCT02750410ApprovedCompleted
NCT01667900Phase 1Completed
NCT01394952Phase 3Completed

Competing Products

20 competing products in Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lorcaserin hydrochloride + PlaceboEisaiApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
Midazolam + AZD5718AstraZenecaPhase 1
29